Embecta (EMBC) Stock Overview
A medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
EMBC Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Embecta Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.13 |
| 52 Week High | US$15.29 |
| 52 Week Low | US$2.77 |
| Beta | 0.85 |
| 1 Month Change | 0.59% |
| 3 Month Change | 64.95% |
| 1 Year Change | -66.18% |
| 3 Year Change | -66.86% |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Seeking Alpha • Aug 25
The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products
Summary Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize. I rate EMBC a Buy under $7, with Strong Buy territory pegged below $4, citing takeover potential and defensive sector appeal amid market rotation. Read the full article on Seeking Alpha
Narrative Update • Jul 14
EMBC: Wound Care Expansion Will Support Future Upside Despite Legal And Medtech Headwinds
Analysts have cut their Embecta price targets sharply, with one key target moving from $11 to $3 as they factor in weaker medtech sentiment, concerns about utilization and inflation, and a shift in investor focus toward data centers instead of healthcare. Analyst Commentary Recent research on Embecta highlights a sharp reset in expectations as analysts reassess the stock against a tougher backdrop for medtech valuations, higher inflation, and investor interest shifting toward data centers.
Narrative Update • Jun 29
EMBC: Medtech Repricing And Index Removals Will Pressure Future Returns
Analysts have reduced their price target for Embecta to $3 from $11, citing updated views on medtech valuations, regulatory and utilization concerns, and a reset in expectations for revenue growth, profit margins, and forward P/E multiples. Analyst Commentary Recent Street research on Embecta points to a more cautious stance, with multiple bearish analysts trimming price targets and reassessing the stock in light of sector wide pressures in medical technology and concerns around utilization and regulation.
Narrative Update • Jun 15
EMBC: Medtech Reset And Buybacks May Support Future Rebound Potential
Embecta's analyst price targets have been sharply reset lower, with one major firm cutting its view to $3 from $11 as analysts factor in what they see as tougher medtech valuations tied to slower product cycles, healthcare utilization concerns, inflation pressures after recent conflicts, and investor preference for data center exposure over healthcare. Analyst Commentary Recent research commentary around Embecta has centered on recalibrating expectations for medtech stocks in light of slower product cycles, healthcare utilization questions, and cost pressures tied to inflation.Narrative Update • Jun 01
EMBC: Sector Reset And Buybacks Will Shape Future Upside Potential
The Street’s view on Embecta has reset sharply, with the average analyst price target moving from about $11 to around $5 as analysts recalibrate for lower P/E assumptions and sector wide pressure on medtech valuations. This pressure is tied to slower product cycles, utilization concerns, higher inflation, and capital flowing to data centers instead of healthcare.Narrative Update • May 16
EMBC: Reset Expectations And Capital Returns Will Shape The Bullish Case
Analysts have reset Embecta's fair value estimate from $25 to $11, reflecting lower price targets after recent cuts from firms that cited updated views on growth, profitability and risk. Analyst Commentary Recent research updates point to a more cautious stance on Embecta's valuation, with several firms lowering their price targets and, in at least one case, issuing a downgrade.Narrative Update • Apr 30
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.Narrative Update • Apr 15
EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Narrative Update • Feb 18
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Analysis Article • Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...Analysis Article • Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...Analysis Article • Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...Narrative Update • Feb 03
EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.Narrative Update • Jan 20
EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Analysis Article • Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...Narrative Update • Jan 05
EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).Narrative Update • Dec 15
EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.Analysis Article • Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
It's been a sad week for Embecta Corp. ( NASDAQ:EMBC ), who've watched their investment drop 14% to US$12.57 in the...Analysis Article • Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it saw a significant share price rise of 36...Analysis Article • Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for Embecta is US$27.21 based on 2 Stage Free Cash Flow to Equity Embecta's...Analysis Article • Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Despite an already strong run, Embecta Corp. ( NASDAQ:EMBC ) shares have been powering on, with a gain of 29% in the...Narrative Update • Aug 10
GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Analysis Article • Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 11.4x might make it look like a buy right now...Analysis Article • May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Analysis Article • May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Analysis Article • Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.29 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • Feb 28
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Summary Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. However, the expanding diabetes care market should partially offset these headwinds, leading to flat topline growth in the coming years. Even though the company is going to post a flat topline, its valuation is such that the business is going to go bust in some time. This situation offers a good risk reward to go long on the stock. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
New Initiatives Expected To Make Embecta More Profitable
Summary Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. I have upgraded the rating on EMBC stock to a Buy, expecting a 12.0% share price increase over the next year, driven by restructuring and new revenue streams. Read the full article on Seeking AlphaAnalysis Article • Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Embecta Corp. ( NASDAQ:EMBC ) will pay a dividend of $0.15 on the 18th of December. The dividend yield will be 2.9...Analysis Article • Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Analysis Article • Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 12.6x might make it look like a buy right now...
New Narrative • Sep 16
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Shareholder Returns
| EMBC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.9% | 0.7% | -1.1% |
| 1Y | -66.2% | -15.8% | 11.7% |
Return vs Industry: EMBC underperformed the US Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: EMBC underperformed the US Market which returned 11.7% over the past year.
Price Volatility
| EMBC volatility | |
|---|---|
| EMBC Average Weekly Movement | 11.6% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EMBC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EMBC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 1,850 | Dev Kurdikar | www.embecta.com |
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors.
Embecta Corp. Fundamentals Summary
| EMBC fundamental statistics | |
|---|---|
| Market cap | US$290.95m |
| Earnings (TTM) | US$87.50m |
| Revenue (TTM) | US$1.02b |
3.3x
P/E Ratio0.3x
P/S RatioIs EMBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBC income statement (TTM) | |
|---|---|
| Revenue | US$1.02b |
| Cost of Revenue | US$423.60m |
| Gross Profit | US$595.10m |
| Other Expenses | US$507.60m |
| Earnings | US$87.50m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.54 |
| Gross Margin | 58.42% |
| Net Profit Margin | 8.59% |
| Debt/Equity Ratio | -237.5% |
How did EMBC perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/17 18:51 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Embecta Corp. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |